புதுப்பிப்புகள்
டீல்
டீல் மதிப்பு—
டீல் vs வணிகம்Phase-I 12,000 sq ft operational; Phase-II injectables civil complete with trials in early 2027; expected steady-state addition of ~30-35% to revenue base
செயல்படுத்தும் காலம்2.0 ஆண்டு
அடிப்படை தரம்B
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)8.0% / 35.0%
EPS உயர்வு45.0%
அப்சைடு பேஸ் / புல் / பேர்55.0% / 125.0% / -35.0%
கால எல்லை18-36 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம்(30 செப். 2026)₹86.0
சமீபத்திய முடிவு விலை(11 நவ. 2026)₹90.0
தொடங்கியதிலிருந்து வருமானம்+4.7%
α vs Smallcap 250+5.1%
α vs சொந்தத் துறை90+ நாட்கள் வைத்திருந்த பிறகு மட்டுமே காட்டப்படும் — மருந்துகள் - இந்திய - ஃபார்முலேஷன்ஸ் இடைநிலை -0.2%, முதிர்ச்சியடைந்த 27 பரிந்துரைகளின் அடிப்படையில்
நேர்மறைகள்
- Phase-I operationalization immediately alleviates packaging bottlenecks and operationalizes a 12,000 sq ft facility
- Phase-II civil completion keeps the high-margin injectables and oncology strategy on schedule for early 2027 trial runs
- Prudent capital structure with debt at only INR 8 Cr versus net worth of INR 96 Cr (D/E 0.08)
- Strong promoter alignment with 66.8% holding and zero reported pledge
- Significant re-rating potential given deep valuation discount versus formulation peers (peer median P/E 35.7x)
அபாயங்கள்
- Sterile injectables execution risk: trial runs, stability testing, and USFDA/regulatory approvals can face protracted delays
- Raw material price sensitivity: FY25 gross margins compressed 1,300 bps to 23.8% due to inability to pass on input costs
- Substantial financial data gap with only Jun 2024 quarterly data reported, obscuring recent trailing performance
- Near-term margin drag from increased overheads and depreciation ahead of Phase-II commercialization
முழு AI சுருக்கம்
1. Ramp-Aware Catalyst & Impact Arithmetic
Quest Laboratories has operationalized its 12,000 sq. ft. Phase-I facility (housing finished goods storage, blister packaging, and quality control) and completed civil construction for the Phase-II Injection Section, targeting trial runs in January-February 2027.
- Baseline Business: Based on the Jun 2024 quarter (Revenue: INR 41.55 Cr, PAT: INR 3.77 Cr, EPS: INR 3.41), the company runs at an annualized run-rate of ~INR 166 Cr revenue and ~INR 15 Cr PAT. At the as-of price of INR 87, implied market capitalization is approximately INR 96 Cr, trading near 1.0x Price-to-Book (Net worth: INR 96 Cr) and ~6.4x annualized P/E.
- Year-1 Ramp (FY27): Phase-I primarily optimizes workflow, debottlenecks packaging, and integrates the planned capsule line (~INR 10-12 Cr annual revenue). Commercial injection production will not materialize in Year 1 due to trial runs scheduled for Jan-Feb 2027, followed by mandatory validation and stability studies. Year-1 revenue uplift is realistically modeled at 6-8% (~INR 10-13 Cr), yielding modest incremental PAT of ~INR 1.2-1.5 Cr.
- Steady-State Ramp (FY28-FY29): Commercialization of the injectable and oncology lines is expected to add INR 50-60 Cr annually (+30-35% on current baseline). Because injectables and oncology products command significantly higher gross margins (45-55%) compared to the basic oral formulations (gross margin compressed to 23.8% in FY25), steady-state operating margins should expand by 250-350 bps, driving an estimated steady-state EPS uplift of ~45%.
2. Industry Context, Capital Intensity & Execution Difficulty
- Industry Structure: Indian formulations is a structurally growing segment (10-12% CAGR), with high-potency injectables and oncology growing at 12-15%.
- Capital Intensity: Medium. Cleanroom setup, isolators, and USFDA-grade utilities require moderate upfront capital, but once operational, working capital cycles and asset turns (2.0-2.5x) are superior to heavy infrastructure or bulk API manufacturing.
- Execution Difficulty: High. Unlike oral solids, sterile liquid and lyophilized injectables carry zero tolerance for contamination. Validating HVAC systems, water-for-injection (WFI) loops, media fills, and stability batches typically spans 6 to 12 months post-trial before full commercial batch release.
3. மல்டிபேக்கர் தர மதிப்பீடு
- Capital Efficiency: ROCE stands at 18.0%, comfortably clearing the quality hurdle.
- Balance Sheet Resilience: Debt is minimal at INR 8 Cr against INR 96 Cr in equity (D/E of 0.08), ensuring the company will not face solvency stress during expansion.
- Ownership Structure: Promoter holding is rock solid at 66.8% across quarters.
- Pricing Power & Margins: A major vulnerability is input cost pass-through. A 51.5% raw material cost increase in FY25 compressed gross margins from 36.7% to 23.8%. The strategic move into injectables is vital to restore margins above 15%.
4. Valuation Scenarios (Horizon: 18-36 Months)
- Base Case (+55% Upside to ~INR 135): Phase-I capsule line delivers INR 10-12 Cr; Phase-II injectables achieve commercial validation by mid-2027 with domestic ramp; PAT expands to ~INR 21 Cr; P/E re-rates mildly from 6.4x to 10-11x.
- Bull Case (+125% Upside to ~INR 195): Rapid commercialization of injectables and oncology export clearance; gross margins recover to >32%; PAT reaches INR 27-30 Cr; valuation re-rates to 18x P/E (half of peer median 35.7x).
- Bear Case (-35% Downside to ~INR 56): Extended trial failures or regulatory compliance hurdles push Phase-II commercialization into late 2028; fixed overheads drag ROCE down below 10%; margin compression persists.
5. தீர்ப்பின் காரணம்
Quest Laboratories is an appealing micro-cap candidate executing an organic transition from commoditized oral formulations into high-barrier injectables with virtually zero leverage. However, the verdict is constrained to POSSIBLE (Score: 58/100) and confidence is capped at 0.45 due to the complete lack of quarterly P&L data for the trailing 8 quarters, combined with proven margin fragility during input price spikes.
2026-09-29 நிலவரப்படி பகுப்பாய்வு (விலை ₹87.05) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
